KPV

What is KPV?

KPV is a tripeptide made of the amino acids lysine, proline, and valine (Lys-Pro-Val). It corresponds to the C-terminal fragment — residues 11 to 13 — of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring signaling peptide in the melanocortin system. Because it is only the tail end of that larger hormone, KPV is studied mainly for the anti-inflammatory part of α-MSH’s activity, and research reports that it does not produce the skin-darkening (pigmentary) effects associated with the full-length hormone.

As a very small peptide, KPV is of interest to researchers partly because small fragments can sometimes retain a specific biological activity while being simpler to make and characterize. It is an investigational research compound and is not an approved drug.

How KPV is described to work

Unlike the full α-MSH hormone, KPV appears to act largely independently of the cell-surface melanocortin receptors. In gut tissue, research describes KPV being taken up into cells through PepT1, a transporter that normally carries di- and tripeptides. Once inside the cell, KPV is reported to interfere with pro-inflammatory signaling pathways — notably NF-κB and the MAPK cascade — which are central switches that turn on inflammatory gene programs.

The downstream consequence reported in model systems is a reduction in the release of inflammatory mediators such as TNF-α, interleukin-6 (IL-6), and IL-1β. This intracellular, receptor-independent route is part of why KPV has been studied in inflammation models rather than as a pigmentation agent.

Reported effects and research areas

Across cell and animal studies, KPV has been examined mostly for anti-inflammatory and tissue-repair endpoints. Reported research areas include models of colitis and inflammatory bowel disease, where reduced intestinal inflammation has been described; skin and dermatology models, including keratinocyte and fibroblast systems and dermatitis; and wound-healing endpoints. KPV has also appeared in some cosmetic and topical formulation research. These are descriptions of laboratory findings only and are not claims that KPV treats, cures, or prevents any condition in people.

What the evidence shows

The bulk of the KPV literature is preclinical — that is, in vitro (cell) and animal studies. Robust, large-scale human clinical-trial data are limited, and KPV is not approved by the FDA for any use. Readers evaluating KPV should treat the mechanism and effect descriptions above as findings from research models rather than established clinical outcomes.

On the regulatory side, KPV is one of seven peptides scheduled for discussion at the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026, which is weighing whether certain peptides should be eligible for compounding under section 503A. In the Federal Register notice, the use listed for KPV’s review is “wound healing and inflammatory conditions.” PCAC recommendations are advisory and non-binding, and any change to the 503A list would still require separate rulemaking.

Handling and storage

A specific, well-validated in-vivo half-life for KPV is not clearly established in the published literature, so figures circulated on commercial pages should be treated with caution. In general, research peptides are handled as lyophilized (freeze-dried) powder kept frozen for longer-term storage, with reconstituted solutions kept refrigerated and protected from repeated freeze-thaw cycles. For the underlying concentration and reconstitution math, see the VialHelp reconstitution tools linked below; this site does not provide human-use or dosing instructions.

Cautions

KPV is discussed here strictly as a research compound. Nothing on this page is medical advice or guidance for human use. Material quality varies between sources, so a batch-specific Certificate of Analysis — covering identity, purity, and endotoxin testing — is the most relevant document when assessing any research peptide. See our guide on reading a COA for detail.

Frequently asked questions

Is KPV the same as α-MSH?

No. KPV is only the three-amino-acid C-terminal fragment of α-MSH. It is studied for part of the anti-inflammatory activity associated with the parent hormone but, in research reports, does not drive the pigmentation effects of full-length α-MSH.

Is KPV approved or legal to use?

KPV is not FDA-approved. Its compounding status is exactly what the July 23–24, 2026 PCAC meeting is examining. This page is informational and does not advise on obtaining or using it.

Why is KPV studied for gut inflammation?

Research describes KPV entering intestinal cells via the PepT1 transporter and dampening NF-κB/MAPK inflammatory signaling, which is why colitis and IBD models feature prominently in the literature.

Related compounds and further reading

Other peptides on the 2026 PCAC agenda: BPC-157 and TB-500. Browse the full peptide library, and see the latest peptide news on the PCAC review. Working with a vial? Use the reconstitution calculator, and read how to reconstitute peptides and sterile technique.

For informational use only. Not medical advice; consult a qualified healthcare professional. 21+.